Global Neurology Academy

Mechanisms of Action and Long-Term Benefit of Immunomodulators in Multiple Sclerosis

    Multiple sclerosis is an often devastating disease for patients and their families. With the recent emergence of potential disease modifying therap...

    Available credits: 2.00


    Valid until:

    Take Post-Test

    If you’ve already completed the activity.

    • Overview

      Multiple sclerosis is an often devastating disease for patients and their families. With the recent emergence of potential disease modifying therapies, early and correct diagnosis is the new cornerstone for standard-of-care, as well as the new baseline from which hope has grown for 1) effective treatments; and 2) quality of life maintenance. Central in this effort is appreciation of clinical, environment and genetic, and paraclinical prognostic indicators with a focused appreciation for what magnetic resonance imaging is bringing to this effort. But MS care is more than just a correct and timely diagnosis, it includes the need for a multidisciplinary team of physicians and other health care personnel who collectively optimize the outcome for each individual patient. As such, educational and practice needs have been identified that are addressed in this initial series of modules, written and reviewed by global faculty.

      With this as backdrop, the Global Multiple Sclerosis Academy is pleased to present this e-learning module entitled “Mechanisms of Action and Long-term Benefit of Immunomodulators in Multiple Sclerosis.” This module addresses for the participant mechanisms of action of a wide range of agents used in the management of multiple sclerosis, from the classical agents interferon-beta and glatiramer acetate, through use of alemtuzumab and daclizumab. Their critical value in the treatment of multiple sclerosis is discussed in depth

    • Learning Objectives

      At the completion of this module, participants will be better able to:

      1. Recognise the different interferon-beta formulations and appreciate the historic and current value of interferon-beta and glatiramer acetate in managing MS.
      2. Recognise the place in MS therapy for dimethyl fumarate, teriflunomide, fingolimod, and mitoxantrone.
      3. Appreciate the use and risk management required when using natalizumab or alemtuzumab in the treatment of patients with MS.
      4. Recognise the mechanism of action and potential clinical efficacy of rituximab, ocrelizumab, and daclizumab in the treatment of patients with MS.
    • Target Audience

      This course is designed to meet the Continuing Medical Education needs of the practicing neurologist.

    • Commercial Support

      This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.
      Original Release Date: 6 October 2015
      Expiration Date: 6 October 2017

    • Accreditation and Credit Designation Statements

      Mechanisms of Action and Long-term Benefit of Immunomodulators in Multiple Sclerosis, made available on and organized by Siyemi Learning and TOPEC Global, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.

      The course, Mechanisms of Action and Long-term Benefit of Immunomodulators in Multiple Sclerosis, made available on and organized by Siyemi Learning and TOPEC Global, is awarded 2 European CME credits (ECMEC). Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 2 CreditsTM. Information on the process to convert EACCME credit to AMA credit can be found at

      Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited.

      The Global Multiple Sclerosis Academy e-Learning Modules, are scanning activities as defined by the Maintenance of Certification (MOC) Program of the Royal College of Physicians and Surgeons of Canada. Scanning is included under Section 2 of the MOC Program. Participants may record .5 credits per module.

    • Disclosure of Conflicts of Interest

      Course Director

      Gavin Giovannoni, MBBCh, PhD
      Professor of Neurology
      Centre Lead for Neuroscience and Trauma
      Barts and the London
      London, United Kingdom
      Financial Relationship Disclosure
      Steering Committee: AbbVie, Biogen-Idec, Novartis, TEVA, Roche
      Consultant: Biogen-Idec, GW Pharma, Merck-Serono, Novartis, Genzyme Sanofi, Fiveprime, Ironwood, Synthon BV, Vertex Pharmaceuticals
      Clinical Advisor: Canbex


      Jaume Sastre-Garriga, MD
      Neurologu/Neuroimmunology Department and MS Centre of Catalonia (Cemcat)
      Hospital Universitari Vall d'Hebron
      Barcelona, Spain
      Financial Relationship Disclosure
      Consultant: BIOGEN, Almirall, Novartis
      Speaker's Bureau: TEVA, Merck-Serono, Novartis, Genzyme

      Antonio Uccelli, MD
      Associate Professor
      University of Genoa
      Genoa, Italy
      Financial Relationship Disclosure
      Consultant: TEVA, Merck-Serono, Bayer, Novartis, Roche, Allergan, Genetech, Sanofi Aventis, Biogen, Genzyme


      J. Theodore Phillips, MD, PhD, FAAN
      Attending Neurologist
      Baylor University Medical Center
      Dallas, TX
      Financial Relationship Disclosure
      Grant support: Biogen Idec, Roche
      Consultant: Acorda, Biogen Idec, Genzyme, Merck-Serono, Sanofi Aventis, Xenoport
      Speaker's Bureau: Acorda, Biogen Idec, Genzyme, Sanofi Aventis

    • System Requirements

      Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

    Facebook Comments

    Sign-up for the Global Neurology Academy newsletters.
    Comprehensive Neurology Education.

    Better education for a better you.

    * Required